{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:08:40Z","timestamp":1791216520655,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010227","name":"Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau","doi-asserted-by":"publisher","award":["ZKX22038"],"award-info":[{"award-number":["ZKX22038"]}],"id":[{"id":"10.13039\/501100010227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02665-7","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T04:54:54Z","timestamp":1753678494000},"page":"2703-2711","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of beinaglutide with continuous subcutaneous infusion in newly diagnosed patients with type 2 diabetes: a randomized, control, open-labeled clinical trial"],"prefix":"10.1007","volume":"48","author":[{"given":"Yi","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-qing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-hui","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9383-2559","authenticated-orcid":false,"given":"Jian-hua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"1","key":"2665_CR1","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1186\/s12889-022-13759-9","volume":"22","author":"Y Yan","year":"2022","unstructured":"Yan Y, Wu T, Zhang M et al (2022) Prevalence, awareness and control of type 2 diabetes mellitus and risk factors in Chinese elderly population. BMC Public Health 22(1):1382. https:\/\/doi.org\/10.1186\/s12889-022-13759-9","journal-title":"BMC Public Health"},{"key":"2665_CR2","doi-asserted-by":"publisher","unstructured":"Sun H, Saeedi P, Karuranga S et al (2022) IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183109119. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119","DOI":"10.1016\/j.diabres.2021.109119"},{"issue":"6","key":"2665_CR3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1463-1326.2006.00686.x","volume":"9","author":"D Russell-Jones","year":"2007","unstructured":"Russell-Jones D, Khan R (2007) Insulin-associated weight gain in diabetes\u2013causes, effects and coping strategies. Diabetes Obes Metab 9(6):799\u2013812. https:\/\/doi.org\/10.1111\/j.1463-1326.2006.00686.x","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2665_CR4","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1464-5491.2005.01501.x","volume":"22","author":"LA Donnelly","year":"2005","unstructured":"Donnelly LA, Morris AD, Frier BM et al (2005) Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med 22(6):749\u2013755. https:\/\/doi.org\/10.1111\/j.1464-5491.2005.01501.x","journal-title":"Diabet Med"},{"issue":"1","key":"2665_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/dc13-2112","volume":"37","author":"DM Nathan","year":"2014","unstructured":"Nathan DM (2014) The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 37(1):9\u201316. https:\/\/doi.org\/10.2337\/dc13-2112","journal-title":"Diabetes Care"},{"key":"2665_CR6","doi-asserted-by":"publisher","unstructured":"(2007) Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 50(6):1140\u20131147. https:\/\/doi.org\/10.1007\/s00125-007-0599-y","DOI":"10.1007\/s00125-007-0599-y"},{"issue":"4","key":"2665_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/dom.12596","volume":"18","author":"S Madsbad","year":"2016","unstructured":"Madsbad S (2016) Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 18(4):317\u2013332. https:\/\/doi.org\/10.1111\/dom.12596","journal-title":"Diabetes Obes Metab"},{"key":"2665_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2018.11.015","author":"L Tao","year":"2019","unstructured":"Tao L, Wang L, Yang X et al (2019) Recombinant human glucagon-like peptide-1 protects against chronic intermittent hypoxia by improving myocardial energy metabolism and mitochondrial biogenesis. Mol Cell Endocrinol. https:\/\/doi.org\/10.1016\/j.mce.2018.11.015","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"2665_CR9","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/osp4.342","volume":"5","author":"YL Zhang","year":"2019","unstructured":"Zhang YL, Zhou C, Li XF et al (2019) Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study. Obes Sci Pract 5(4):366\u2013375. https:\/\/doi.org\/10.1002\/osp4.342","journal-title":"Obes Sci Pract"},{"issue":"4","key":"2665_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM et al (2017) Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 5(4):251\u2013260. https:\/\/doi.org\/10.1016\/S2213-8587(17)30013-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2665_CR11","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1016\/j.numecd.2021.07.015","volume":"31","author":"V Guarnotta","year":"2021","unstructured":"Guarnotta V, Bianco MJ, Vigneri E et al (2021) Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis 31(11):3193\u20133201. https:\/\/doi.org\/10.1016\/j.numecd.2021.07.015","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"10","key":"2665_CR12","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1111\/dom.14469","volume":"23","author":"JP Frias","year":"2021","unstructured":"Frias JP, Bonora E, Nev\u00e1rez Ruiz L et al (2021) Efficacy and safety of dulaglutide 3.0 and 4.5\u00a0mg in patients aged younger than 65 and 65 years or older: post hoc analysis of the AWARD-11 trial. Diabetes Obes Metab 23(10):2279\u20132288. https:\/\/doi.org\/10.1111\/dom.14469","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2665_CR13","doi-asserted-by":"publisher","first-page":"103382","DOI":"10.1016\/j.isci.2021.103382","volume":"24","author":"F Zhang","year":"2021","unstructured":"Zhang F, Chen Z, Wu D et al (2021) Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice. iScience 24(12):103382. https:\/\/doi.org\/10.1016\/j.isci.2021.103382","journal-title":"iScience"},{"issue":"1","key":"2665_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1677\/joe.0.1380159","volume":"138","author":"RM Elliott","year":"1993","unstructured":"Elliott RM, Morgan LM, Tredger JA et al (1993) Glucagon-like peptide-1 (7\u201336)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 138(1):159\u2013166. https:\/\/doi.org\/10.1677\/joe.0.1380159","journal-title":"J Endocrinol"},{"issue":"9309","key":"2665_CR15","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","volume":"359","author":"M Zander","year":"2002","unstructured":"Zander M, Madsbad S, Madsen JL et al (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359(9309):824\u2013830. https:\/\/doi.org\/10.1016\/S0140-6736(02)07952-7","journal-title":"Lancet"},{"issue":"4","key":"2665_CR16","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1177\/19322968211000441","volume":"16","author":"A Baumstark","year":"2022","unstructured":"Baumstark A, Mende J, Uchiyama J et al (2022) Description of a novel patch pump for insulin delivery and comparative accuracy evaluation. J Diabetes Sci Technol 16(4):971\u2013975. https:\/\/doi.org\/10.1177\/19322968211000441","journal-title":"J Diabetes Sci Technol"},{"key":"2665_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13483","author":"X Liu","year":"2023","unstructured":"Liu X, Yang W, Liu J et al (2023) The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open-label, randomized trial. J Diabetes. https:\/\/doi.org\/10.1111\/1753-0407.13483","journal-title":"J Diabetes"},{"issue":"7","key":"2665_CR18","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.2337\/dc09-0076","volume":"32","author":"J Zhou","year":"2009","unstructured":"Zhou J, Li H, Ran X et al (2009) Reference values for continuous glucose monitoring in Chinese subjects. Diabetes Care 32(7):1188\u20131193. https:\/\/doi.org\/10.2337\/dc09-0076","journal-title":"Diabetes Care"},{"key":"2665_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/903524","author":"FF Li","year":"2015","unstructured":"Li FF, Xu XH, Fu LY et al (2015) Influence of acarbose on plasma glucose fluctuations in Insulin-Treated patients with type 2 diabetes: A pilot study. Int J Endocrinol. https:\/\/doi.org\/10.1155\/2015\/903524","journal-title":"Int J Endocrinol"},{"key":"2665_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6618257","author":"LL Jiang","year":"2021","unstructured":"Jiang LL, Zhang P, Liu BL et al (2021) Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial. Biomed Res Int. https:\/\/doi.org\/10.1155\/2021\/6618257","journal-title":"Biomed Res Int"},{"issue":"9626","key":"2665_CR21","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/S0140-6736(08)60762-X","volume":"371","author":"J Weng","year":"2008","unstructured":"Weng J, Li Y, Xu W et al (2008) Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371(9626):1753\u20131760. https:\/\/doi.org\/10.1016\/S0140-6736(08)60762-X","journal-title":"Lancet"},{"issue":"7","key":"2665_CR22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412\u2013419. https:\/\/doi.org\/10.1007\/BF00280883","journal-title":"Diabetologia"},{"issue":"4","key":"2665_CR23","first-page":"419","volume":"29","author":"X Li","year":"2004","unstructured":"Li X, Zhou ZG, Qi HY et al (2004) [Replacement of insulin by fasting C-peptide in modified homeostasis model assessment to evaluate insulin resistance and islet beta cell function]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 29(4):419\u2013423","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"issue":"2","key":"2665_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1089\/dia.2017.0283","volume":"20","author":"R Chlup","year":"2018","unstructured":"Chlup R, Runzis S, Castaneda J et al (2018) Complex assessment of metabolic effectiveness of insulin pump therapy in patients with type 2 diabetes beyond HbA1c reduction. Diabetes Technol Ther 20(2):153\u2013159. https:\/\/doi.org\/10.1089\/dia.2017.0283","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"2665_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.20945\/2359-3997000000388","volume":"65","author":"G Wang","year":"2021","unstructured":"Wang G, Wu P, Qiu Y et al (2021) Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight\/obesity. Arch Endocrinol Metab 65(4):421\u2013427. https:\/\/doi.org\/10.20945\/2359-3997000000388","journal-title":"Arch Endocrinol Metab"},{"key":"2665_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15360","author":"K Chen","year":"2023","unstructured":"Chen K, Chen L, Shan Z et al (2023) Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study. Diabetes Obes Metab. https:\/\/doi.org\/10.1111\/dom.15360","journal-title":"Diabetes Obes Metab"},{"key":"2665_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1156521","author":"Q Wen","year":"2023","unstructured":"Wen Q, Fang S, Liang Y et al (2023) Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2023.1156521","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2665_CR28","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1055\/a-1608-0345","volume":"130","author":"L Gao","year":"2022","unstructured":"Gao L, Huang H, Zhang L et al (2022) Comparison of beinaglutide versus Metformin for weight loss in overweight and obese Non-diabetic patients. Exp Clin Endocrinol Diabetes 130(6):358\u2013367. https:\/\/doi.org\/10.1055\/a-1608-0345","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"6","key":"2665_CR29","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1210\/jc.2018-00070","volume":"103","author":"HW Rodbard","year":"2018","unstructured":"Rodbard HW, Lingvay I, Reed J et al (2018) Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): A randomized, controlled trial. J Clin Endocrinol Metab 103(6):2291\u20132301. https:\/\/doi.org\/10.1210\/jc.2018-00070","journal-title":"J Clin Endocrinol Metab"},{"key":"2665_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(16)30006-4","author":"B Cariou","year":"2015","unstructured":"Cariou B (2015) Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association. Diabetes Metab. https:\/\/doi.org\/10.1016\/S1262-3636(16)30006-4","journal-title":"Diabetes Metab"},{"issue":"4","key":"2665_CR31","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s12325-019-00914-9","volume":"36","author":"JM Lu","year":"2019","unstructured":"Lu JM (2019) The role of Glucagon-Like Peptide-1 receptor agonists in type 2 diabetes in Asia. Adv Ther 36(4):798\u2013805. https:\/\/doi.org\/10.1007\/s12325-019-00914-9","journal-title":"Adv Ther"},{"issue":"9662","key":"2665_CR32","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","volume":"373","author":"A Garber","year":"2009","unstructured":"Garber A, Henry R, Ratner R et al (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373(9662):473\u2013481. https:\/\/doi.org\/10.1016\/S0140-6736(08)61246-5","journal-title":"Lancet"},{"issue":"10","key":"2665_CR33","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1111\/dom.14465","volume":"23","author":"E Bonora","year":"2021","unstructured":"Bonora E, Frias JP, Tinahones FJ et al (2021) Effect of dulaglutide 3.0 and 4.5\u00a0mg on weight in patients with type 2 diabetes: exploratory analyses of AWARD-11. Diabetes Obes Metab 23(10):2242\u20132250. https:\/\/doi.org\/10.1111\/dom.14465","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2665_CR34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/obr.12106","volume":"14","author":"H Wang","year":"2013","unstructured":"Wang H, Zhai F (2013) Programme and policy options for preventing obesity in China. Obes Rev 14 Suppl 14(2):134\u201340. https:\/\/doi.org\/10.1111\/obr.12106","journal-title":"Obes Rev 14 Suppl"},{"issue":"2","key":"2665_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12325-017-0652-2","volume":"35","author":"A Lapolla","year":"2018","unstructured":"Lapolla A, Berra C, Boemi M et al (2018) Long-Term effectiveness of liraglutide for treatment of type 2 diabetes in a Real-Life setting: A 24-Month, multicenter, Non-interventional, retrospective study. Adv Ther 35(2):243\u2013253. https:\/\/doi.org\/10.1007\/s12325-017-0652-2","journal-title":"Adv Ther"},{"issue":"3","key":"2665_CR36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1089\/dia.2005.7.467","volume":"7","author":"T Poon","year":"2005","unstructured":"Poon T, Nelson P, Shen L et al (2005) Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 7(3):467\u2013477. https:\/\/doi.org\/10.1089\/dia.2005.7.467","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"2665_CR37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13300-015-0112-4","volume":"6","author":"P Mezquita-Raya","year":"2015","unstructured":"Mezquita-Raya P, Reyes-Garcia R, Moreno-Perez O et al (2015) Clinical effects of liraglutide in a Real-World setting in spain: eDiabetes-Monitor SEEN diabetes mellitus working group study. Diabetes Ther 6(2):173\u2013185. https:\/\/doi.org\/10.1007\/s13300-015-0112-4","journal-title":"Diabetes Ther"},{"issue":"1","key":"2665_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s13300-016-0222-7","volume":"8","author":"FF Li","year":"2017","unstructured":"Li FF, Jiang L, Fu L et al (2017) Exenatide Add-on to continuous subcutaneous insulin infusion therapy reduces bolus insulin doses in patients with type 2 diabetes: A randomized, controlled, Open-Label trial. Diabetes Ther 8(1):177\u2013187. https:\/\/doi.org\/10.1007\/s13300-016-0222-7","journal-title":"Diabetes Ther"},{"issue":"3","key":"2665_CR39","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","volume":"15","author":"M Shah","year":"2014","unstructured":"Shah M, Vella A (2014) Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord 15(3):181\u2013187. https:\/\/doi.org\/10.1007\/s11154-014-9289-5","journal-title":"Rev Endocr Metab Disord"},{"key":"2665_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d7771","author":"T Vilsb\u00f8ll","year":"2012","unstructured":"Vilsb\u00f8ll T, Christensen M, Junker AE et al (2012) Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Bmj. https:\/\/doi.org\/10.1136\/bmj.d7771","journal-title":"Bmj"},{"issue":"2","key":"2665_CR41","doi-asserted-by":"publisher","first-page":"e13483","DOI":"10.1111\/1753-0407.13483","volume":"16","author":"X Liu","year":"2023","unstructured":"Liu X, Yang W, Liu J et al (2023) The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open-label, randomized trial. J Diabetes 16(2):e13483. https:\/\/doi.org\/10.1111\/1753-0407.13483","journal-title":"J Diabetes"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02665-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02665-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02665-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:06:30Z","timestamp":1762880790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02665-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["2665"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02665-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}